mental health conditions
Gate Neurosciences plans Phase II MDD trial with next-gen antidepressant
The company aims to start the Phase II study of its lead compound zelquistinel in Q4 2023 at sites in the US.
Mental health disorder rates in the workplace are soaring
FDA accepts Teva-MedinCell’s new drug application for schizophrenia drug
Maternal smoking as potential risk factor for Tourette syndrome among children
FDA approves Alkermes’ Lybalvi for schizophrenia treatment
Major depressive disorder: why does it affect women more?
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
